

UK MHRA revokes Valneva’s IXCHIQ chikungunya vaccine authorization over traveler benefit-risk review. Minimal financial impact expected.
You can purchase shares of Valneva (NASDAQ:VALN) through any online brokerage.
Other companies in Valneva’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Valneva has a consensus price target of $16.00.
The stock price for Valneva (NASDAQ: VALN) is $5.45 last updated October 27, 2026 at 9:28 AM EDT.
There are no upcoming dividends for Valneva.
Valneva does not have any upcoming earnings scheduled.
There is no upcoming split for Valneva.
Valneva is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines...